STAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting down
Artiva Biotherapeutics is shutting down operations following the deaths of two patients enrolled in an autoimmune cell therapy trial. The clinical program aimed to adapt cancer-directed cellular therapy approaches for the treatment of autoimmune indications. The fatal safety events bring a sudden halt to Artiva's development pipeline and force a complete corporate wind-down.
Why it matters: The shutdown poses a critical setback for the biopharma sector's high-profile push to repurpose oncology cell therapies for autoimmune diseases, likely prompting intensified regulatory scrutiny and clinical protocol reassessments across peer pipelines.
Read the full article at statnews.com →
STAT News·